The Ledger / Wolfgang Marguerre & family
Wolfgang Marguerre & family
◼ Origin
German-born entrepreneur who co-founded Octapharma AG in 1983 in Lachen, Switzerland with co-founder Robert Taub, building it from a startup into one of the world's largest privately held manufacturers of plasma-derived human protein therapeutics — including von Willebrand factor/factor VIII therapies (Nuwiq, Wilate) for hemophilia and von Willebrand disease, intravenous immunoglobulin (Octagam) for immunotherapy, and albumin and fibrin sealants for critical care use in surgery and trauma; Octapharma has grown to 7,500+ employees in 30+ countries with manufacturing plants in Germany, Austria, Sweden, France, and the US, and annual revenues exceeding €2B. Marguerre remains chairman of the supervisory board and retains majority family ownership of the privately held company.
◼ Self-Made Verdict — YES
Co-founded Octapharma in 1983 from scratch without an inherited pharmaceutical business or family capital base in the sector; built it over four decades from a startup into one of the world's largest privately held plasma-protein manufacturers through original scientific leadership, manufacturing investment, and international commercial execution. His wealth reflects original founding equity, not inherited business capital.
◼ Documented marks
01
Co-founder and supervisory board chairman of Octapharma AG (Lachen, Switzerland), one of the world's largest privately held manufacturers of plasma-derived human protein therapies; Octapharma processes human blood plasma from 200+ plasma donation centers (primarily in the US) into coagulation factors for hemophilia treatment (Nuwiq, Wilate), intravenous immunoglobulin for immune deficiency and autoimmune diseases (Octagam, Panzyga), and albumin for critical care. The company has 7,500+ employees in 30+ countries and annual revenues exceeding €2B; Marguerre retains majority family ownership in a privately held structure with no institutional investors.
02
Octapharma's US plasma collection operations — which source raw plasma from paid American donors — are a central element of its global supply chain; the company operates one of the largest plasma collection networks in the US through Octapharma Plasma, Inc. Plasma donor compensation practices, particularly the structural reliance on economically distressed populations who donate plasma as a recurring income source, have been a subject of bioethics debate; academic research has documented that US plasma donors disproportionately include low-income individuals for whom plasma compensation is a material income supplement, raising questions about the voluntariness and economic coercion embedded in the US paid-plasma model on which Octapharma and other manufacturers depend.
03
In November 2025, Octapharma AG reached a $2.55M settlement with US state attorneys general over a data breach that exposed personal information — including Social Security numbers, financial information, and medical data — of approximately 547,000 plasma donors following a cyberattack on its US plasma collection systems; the breach was first detected in 2024 and affected donors at Octapharma Plasma centers across multiple US states. The settlement required Octapharma to implement enhanced cybersecurity measures and provide affected individuals with multi-year identity monitoring services. No criminal charges related to the breach were filed.
No inheritance, or primary accounts documented for this billionaire yet.
◼ List of charges
No documented charges yet.
These are moral charges, not legal ones. The actual legal system has not — and will not — bring them.
More ledger entries